Vitamin D in Chronic Kidney Disease and Dialysis Patients.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
cholecalciferol 17 nephrologydiseasesdrugs
chronic kidney disease 2 nephrologydiseases
paricalcitol 4 nephrologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
cholecalciferol 1803 supplementation to prevent SHPT. Many vitamin D supplementation regimens using either ergocalciferol or cholecalciferol daily, weekly or monthly have been reported. The benefit of native vitamin D supplementation remains
cholecalciferol 3327 diet and supplement [[1]]. Vegetable sources provide ergocalciferol (D2) and animal sources provide cholecalciferol (D3); both of these have similar metabolisms. These precursors are transported in the liver by a vitamin
cholecalciferol 8585 [[25]].Jacob et al. reported that chronic hemodialysis patients exhibit defective photoproduction of cholecalciferol , despite normal epidermal content of substrate, 7-dehydrocholesterol [[28]].In transplant recipients,
cholecalciferol 12500 regimens seem efficient for restoring 25(OH)D levels [[58]]. For years, we chose to provide monthly cholecalciferol during dialysis to insure observance [[59]]. Zitt et al. reported that a weekly dosing regimen of 100
cholecalciferol 12989 vitamin D supplementation with the same efficiency [[62]]. In France, nephrologists used to prescribe cholecalciferol as oral 100,000 IU monthly doses, which allow normalization of serum 25(OH)D level in >85% of cases
cholecalciferol 13178 25(OH)D level in >85% of cases [[59]]. In Belgium, Delanaye et al. reported their experience using oral cholecalciferol 25,000 IU every two weeks, which allowed achievement of the recommended targets of >30 ng/mL after 12
cholecalciferol 13416 non-dialysis patients, this is not usually necessary, as according to our experience, 50,000 IU of cholecalciferol monthly is sufficient in most cases.Even though these protocols demonstrated their efficiency, safety
cholecalciferol 17443 decreased PTH [[80]]. We need to determine the dose range for responsiveness using ergocalciferol or cholecalciferol and different protocols (daily, weekly, or monthly administration). However, due to its shorter high
cholecalciferol 17712 monthly regimen. Massart et al. [[56]] and we [[59]] reported increased serum 1,25(OH)2D level after cholecalciferol supplementation. Seibeirt et al. confirmed these data and additionally did not find an increase in FGF-23
cholecalciferol 17941 concentration after vitamin D supplementation [[81]].Aytac et al. reported a favorable effect of high-dose cholecalciferol on cardiovascular and endothelial parameters of children with CKD [[83]] by using flow-mediated dilatation,
cholecalciferol 18184 homocysteine, and von Willebrand factor measurements. Karakas et al. confirmed that eight weeks of cholecalciferol improved the percentage of flow-mediated dilatation in dialysis with CKD patients [[85]]. In diabetic
cholecalciferol 18497 by adding native vitamin D was found by Kim et al. [[82]]. Meireless et al. reported in a RCT that cholecalciferol (50,000 twice weekly) promoted upregulation of CYP27B1 and VDR expression in monocytes and decreased
cholecalciferol 20853 Armas et al. reported that ergocalciferol displays a shorter half-life and is less potent compared with cholecalciferol with the same initial peak, but the serum 25(OH)D plateau decreased quickly after a few days using D2
cholecalciferol 21304 report a superiority for D3 compounds [[94]].More recently, Wetmore et al. reported that therapy with cholecalciferol , compared with ergocalciferol, is more effective at raising serum 25(OH)D in non-dialysis-dependent
cholecalciferol 21811 25(OH)D [[96]].Ergocalciferol is mostly used in the United States. In other countries, such as France, cholecalciferol is the standard form, at least for CKD patients. For dialysis patients, we currently use 100,000 IU
cholecalciferol 21935 standard form, at least for CKD patients. For dialysis patients, we currently use 100,000 IU of oral cholecalciferol monthly.8. VDRA for CKD and Dialysis PatientsAs reported since the 1970s and mostly the 1980s, calcitriol
cholecalciferol 25969 hypercalcemia and hyperphosphatemia were not different between paricalcitol and alfacalcidol [[109]]. Low-dose cholecalciferol in vitamin D-deficient HD patients and paricalcitol in cases of persistent SHPT have been reported to
paricalcitol 25343 cardiovascular events and reduced proteinuria, but resulted in an increased probability of hypercalcemia when paricalcitol was used [[107]]. In an observational study performed in Japan, it was reported that VDRA prescriptions
paricalcitol 25921 treatment of SHPT, biological consequences, hypercalcemia and hyperphosphatemia were not different between paricalcitol and alfacalcidol [[109]]. Low-dose cholecalciferol in vitamin D-deficient HD patients and paricalcitol
paricalcitol 26024 paricalcitol and alfacalcidol [[109]]. Low-dose cholecalciferol in vitamin D-deficient HD patients and paricalcitol in cases of persistent SHPT have been reported to be efficient and to have no side effects [[110]].Lou
paricalcitol 26424 study, in rat with SHPT, the correction of vitamin D deficiency effectively reversed the resistance to paricalcitol induction of CCAAT/Enhancer-binding-protein β (C/EBP-β) to suppress ADAM metallopeptidase domain 17
Select Disease Character Offset Disease Term Instance
chronic kidney disease 637 4/2017AbstractVitamin D deficiency (<20 ng/mL) and insufficiency (20–29 ng/mL) are common among patients with chronic kidney disease (CKD) or undergoing dialysis. In addition to nutritional and sunlight exposure deficits, factors that
chronic kidney disease 5105 more than one billion people are thought to have vitamin D insufficiency or deficiency worldwide.In chronic kidney disease (CKD), the hyperphosphaturic osteocyte-derived hormone FGF-23 increases to compensate for phosphate

You must be authorized to submit a review.